Osiris Therapeutics (OSIR) Volatility Up as Shares Move to 10-Month High
Tweet
Share
E-mailGet Alerts OSIR Hot Sheet
Join SI Premium – FREE
Osiris Therapeutics (Nasdaq: OSIR) is seeing heightened volatility as shares continue higher Monday.
Market data has implied volatility up 5.5 percent from last Friday's close to 71.7 percent.
Last Friday, Osiris said it received market authorization from Health Canada to market its stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. Shares popped 5.5 percent following that announcement.
Osiris stock is up an additional 26 percent Monday to the highest levels seen since last August.
Market data has implied volatility up 5.5 percent from last Friday's close to 71.7 percent.
Last Friday, Osiris said it received market authorization from Health Canada to market its stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. Shares popped 5.5 percent following that announcement.
Osiris stock is up an additional 26 percent Monday to the highest levels seen since last August.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Snowflake (SNOW) call put ratio 2.8 calls to 1 put into quarter results
- SpaceX (SPCX) call put ratio 2 calls to 1 put
- PBOC To Boost Credit Support For China's Property Sector
Create E-mail Alert Related Categories
Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
